Key facts
- PozeSCAF’s last known valuation is $6.7M (Jun 2023).
- It has raised $3.8M; the latest was Seed Round ($2.0M) in Jan 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for PozeSCAF
- ·The full record, as it builds
Funding rounds
No funding rounds for PozeSCAF are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PozeSCAF
Developer of a generative AI-based drug discovery platform designed to create quality lead candidates for preclinical research. The company offers an integrated approach combining in-house AI technology, computational chemistry, and synthetic chemistry capabilities, enabling pharmaceutical and biotech companies to accelerate drug development with improved candidate quality.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 32
- Website
- pozescaf.com/
- Ownership
- Privately Held (backing)
PozeSCAF doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PozeSCAF shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PozeSCAF in its N-PORT filings yet. We sweep new filings monthly.